TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Enlivex ( (ENLV) ) has shared an update.
On September 11, 2025, Enlivex Therapeutics announced positive results from its Phase IIa trial of Allocetra™ for knee osteoarthritis, demonstrating significant improvements in pain and function. The company plans to advance to a Phase IIb trial in 2026, with six-month data expected in November 2025. These results position Enlivex as a strong candidate for partnerships and funding opportunities, potentially transforming treatment options for the growing population affected by KOA.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company focused on macrophage reprogramming immunotherapy. The company is based in Nes Ziona, Israel, and is engaged in developing therapies for conditions such as knee osteoarthritis (KOA).
Average Trading Volume: 546,365
Technical Sentiment Signal: Sell
Current Market Cap: $24.22M
Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.